SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally is centered on the pending FDA decision on deramiocel for Duchenne muscular dystrophy: management reiterated confidence on its earnings call and said the application is in final review, while traders interpret its comments about labeling as a possible positive signal. Bulls are anticipating approval and short covering, but others stress that the outcome remains uncertain and a rejection is still possible.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Record Q3 revenue growth and Rumbles first positive adjusted EBITDA quarter, driven largely by Quake AIs GPU-computing business, have renewed interest in its shift toward AI infrastructure. Bulls are emphasizing execution and heavy short interest, while skeptics point to continued GAAP losses, financing needs, possible data-center delays and a softer Q4 outlook.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA for sonelokimab in hidradenitis suppurativa and the pending FDA filing-review decision dominate discussion, alongside the drugs clinical prospects. Traders are divided between optimism about the pipeline and a potential buyout, and concerns about regulatory risk, competition, and the cost of commercializing the drug independently.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras positive Phase 2 results for ABCL635, its investigational treatment for menopausal hot flashes, and CEO comments on its commercial potential are driving attention, alongside Q3 results, pipeline additions and analyst upgrades. The community is largely bullish, but some traders are frustrated by the weak price reaction and emphasize that durability and later-stage trial execution remain unproven.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A hotter-than-expected CPI reading has lifted the dollar and Treasury yields, while renewed Fed rate-hike bets weigh on gold and GLD. Traders are divided between calling the decline a deeper selloff and looking for a rebound or buying opportunity, with some questioning golds safe-haven behavior.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels sharp, sustained decline and underperformance versus uranium and rare-earth peers dominate discussion. Traders point to dilution and funding concerns, risks around the VAC acquisition and capital-intensive rare-earth expansion, and broader market and China-trade uncertainty; bullish investors are still accumulating on the long-term uranium and domestic supply-chain thesis, while bears question execution and shareholder value.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinals steep selloff is being attributed mainly to concerns over its Hughes Brothers acquisition, with traders questioning the deals cost, potential dilution, and managements handling of margins and capital allocation. Some also point to securities-law investigations and loss of investor confidence, while bullish traders argue the shares are oversold and undervalued.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A strong Q3 report, raised outlook and record backlog sparked a sharp rally, with the CEOs cancellation of his planned stock-sale program adding to bullish sentiment and talk of short covering. Traders remain divided: bulls point to robust AI-compute demand and customer prepayments, while skeptics focus on heavy debt, financing costs and potential dilution.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines quarterly update highlighted a strong early launch for RASONQUE, its newly approved pancreatic cancer drug, but the shares sold off despite the upbeat sales reception. Traders are debating whether the decline reflects profit-taking and concerns about sustaining the launch amid high spending, or an overreaction to results that otherwise showed promising initial demand.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths fiscal Q1 results are driving discussion: traders point to expanding margins and a record backlog, while others focus on revenue missing expectations and supply-chain delays that could slow deliveries. The bullish case centers on defense demand and drone-optics orders, but is tempered by concerns about execution and weak share performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
